Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.72
BEAT's Cash to Debt is ranked higher than
80% of the 247 Companies
in the Global Medical Care industry.

( Industry Median: 0.21 vs. BEAT: 0.72 )
BEAT' s 10-Year Cash to Debt Range
Min: 0.13   Max: No Debt
Current: 0.72

Equity to Asset 0.53
BEAT's Equity to Asset is ranked higher than
76% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. BEAT: 0.53 )
BEAT' s 10-Year Equity to Asset Range
Min: -1.16   Max: 0.92
Current: 0.53

-1.16
0.92
F-Score: 4
Z-Score: 0.54
M-Score: -3.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4.63
BEAT's Operating margin (%) is ranked higher than
53% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 9.51 vs. BEAT: -4.63 )
BEAT' s 10-Year Operating margin (%) Range
Min: -160.62   Max: 8.05
Current: -4.63

-160.62
8.05
Net-margin (%) -7.63
BEAT's Net-margin (%) is ranked higher than
53% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 5.22 vs. BEAT: -7.63 )
BEAT' s 10-Year Net-margin (%) Range
Min: -160.04   Max: 7.64
Current: -7.63

-160.04
7.64
ROE (%) -17.61
BEAT's ROE (%) is ranked higher than
51% of the 241 Companies
in the Global Medical Care industry.

( Industry Median: 8.06 vs. BEAT: -17.61 )
BEAT' s 10-Year ROE (%) Range
Min: -158.5   Max: 6.13
Current: -17.61

-158.5
6.13
ROA (%) -9.33
BEAT's ROA (%) is ranked lower than
51% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 3.79 vs. BEAT: -9.33 )
BEAT' s 10-Year ROA (%) Range
Min: -91.86   Max: 5.55
Current: -9.33

-91.86
5.55
ROC (Joel Greenblatt) (%) -23.06
BEAT's ROC (Joel Greenblatt) (%) is ranked higher than
51% of the 249 Companies
in the Global Medical Care industry.

( Industry Median: 14.75 vs. BEAT: -23.06 )
BEAT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -238.29   Max: 21.67
Current: -23.06

-238.29
21.67
Revenue Growth (%) 0.70
BEAT's Revenue Growth (%) is ranked higher than
62% of the 205 Companies
in the Global Medical Care industry.

( Industry Median: 6.10 vs. BEAT: 0.70 )
BEAT' s 10-Year Revenue Growth (%) Range
Min: -41   Max: 52.8
Current: 0.7

-41
52.8
EPS Growth (%) -29.30
BEAT's EPS Growth (%) is ranked higher than
56% of the 153 Companies
in the Global Medical Care industry.

( Industry Median: 10.30 vs. BEAT: -29.30 )
BEAT' s 10-Year EPS Growth (%) Range
Min: -34.3   Max: -17.1
Current: -29.3

-34.3
-17.1
» BEAT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

BEAT Guru Trades in Q3 2013

Jim Simons 875,300 sh (+73.67%)
» More
Q4 2013

BEAT Guru Trades in Q4 2013

Jim Simons 664,000 sh (-24.14%)
» More
Q1 2014

BEAT Guru Trades in Q1 2014

George Soros 74,600 sh (New)
Jim Simons 715,800 sh (+7.8%)
» More
Q2 2014

BEAT Guru Trades in Q2 2014

Jim Simons 777,200 sh (+8.58%)
George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with BEAT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$6.78 - $11.02 $ 7.09-11%0
George Soros 2014-03-31 New Buy0.01%$6.88 - $11.71 $ 7.09-22%74600
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
BEAT's P/B is ranked higher than
70% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 3.00 vs. BEAT: 3.00 )
BEAT' s 10-Year P/B Range
Min: 0.42   Max: 5.8
Current: 3

0.42
5.8
P/S 1.30
BEAT's P/S is ranked higher than
74% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 1.62 vs. BEAT: 1.30 )
BEAT' s 10-Year P/S Range
Min: 0.43   Max: 5.88
Current: 1.3

0.43
5.88
EV-to-EBIT -28.64
BEAT's EV-to-EBIT is ranked lower than
56% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 25.93 vs. BEAT: -28.64 )
BEAT' s 10-Year EV-to-EBIT Range
Min: 11.8   Max: 421.2
Current: -28.64

11.8
421.2
Current Ratio 1.17
BEAT's Current Ratio is ranked higher than
65% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 1.53 vs. BEAT: 1.17 )
BEAT' s 10-Year Current Ratio Range
Min: 0.44   Max: 7.88
Current: 1.17

0.44
7.88
Quick Ratio 1.08
BEAT's Quick Ratio is ranked higher than
64% of the 184 Companies
in the Global Medical Care industry.

( Industry Median: 1.35 vs. BEAT: 1.08 )
BEAT' s 10-Year Quick Ratio Range
Min: 0.44   Max: 7.88
Current: 1.08

0.44
7.88

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.62
BEAT's Price/Tangible Book is ranked higher than
68% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 9.92 vs. BEAT: 11.62 )
BEAT' s 10-Year Price/Tangible Book Range
Min: 0.76   Max: 11.67
Current: 11.62

0.76
11.67
Price/DCF (Projected) 6.22
BEAT's Price/DCF (Projected) is ranked higher than
71% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 3.20 vs. BEAT: 6.22 )
BEAT' s 10-Year Price/DCF (Projected) Range
Min: 4.84   Max: 16.21
Current: 6.22

4.84
16.21
Price/Median PS Value 1.20
BEAT's Price/Median PS Value is ranked higher than
70% of the 262 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. BEAT: 1.20 )
BEAT' s 10-Year Price/Median PS Value Range
Min: 0.44   Max: 5.44
Current: 1.2

0.44
5.44
Earnings Yield (Greenblatt) 0.40
BEAT's Earnings Yield (Greenblatt) is ranked lower than
53% of the 236 Companies
in the Global Medical Care industry.

( Industry Median: 5.00 vs. BEAT: 0.40 )
BEAT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 8.5
Current: 0.4

0.2
8.5
Forward Rate of Return (Yacktman) -1.43
BEAT's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 212 Companies
in the Global Medical Care industry.

( Industry Median: 7.71 vs. BEAT: -1.43 )
BEAT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -132.2   Max: 47.2
Current: -1.43

-132.2
47.2

Business Description

Industry: Health Care Providers » Medical Care
Compare: » details
Traded in other countries:C25.Germany
CardioNet, Inc. was initially incorporated in California in 1994, and re-incorporated in Delaware in connection with its initial public offering in March 2008. The company provides ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual's health. The company is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry, event and Holter services. The company has developed an integrated patient monitoring platform that incorporates a wireless data transmission network, internally developed software, FDA-cleared algorithms and medical devices, and a 24-hour monitoring service center. The company has operations into two reportable business segments: service and products. The patient service business segment's principal focus is on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry, event and Holter services. The product business segment, which was developed through the Biotel acquisition in December 2010, focuses on the development, manufacturing, testing and marketing of medical devices and related software to medical companies, clinics and hospitals. The MCOT devices automatically detect a patient's cardiac rhythm irregularities and transmit elecrocardiogram data to a continuously monitored information center.The C3 generation of devices builds upon its current technology by allowing for expanded wireless transmitting capabilities and improved user interface characteristics. The CardioNet Monitoring Center provides analysis and response for all incoming ECG data. Currently, the company provides all cardiac arrhythmia monitoring services for MCOT. The company's MCOT service incorporates a lightweight patient-worn sensor attached to electrodes that capture two-channel ECG data, measuring electrical activity of the heart and communicates wirelessly with a compact, handheld monitor. The monitor analyzes incoming heartbeat-by-heartbeat information from the sensor on a real-time basis by applying proprietary algorithms designed to detect arrhythmias.When the monitor detects an arrhythmic event, it automatically transmits the ECG to the CardioNet Monitoring Center, even in the absence of symptoms noticed by the patient and without patient involvement. At the CardioNet Monitoring Center, which operates 24 hours a day and 7 days per week, experienced certified cardiac monitoring specialists analyze the sent data; respond to urgent events and report results in the manner prescribed by the physician. The MCOT device employs two-way wireless communications, enabling continuous transmission of patient data to the CardioNet Monitoring Center and permitting physicians to remotely adjust monitoring parameters and request previous ECG data from the memory stored in the monitor.
» More Articles for BEAT

Headlines

Articles On GuruFocus.com
CardioNet Inc. Reports Operating Results (10-Q) Nov 09 2010 
CardioNet Inc. Reports Operating Results (10-Q) Aug 02 2010 
CardioNet Inc. Reports Operating Results (10-Q) May 04 2010 
CardioNet Inc. Reports Operating Results (10-Q) Nov 06 2009 
CardioNet Inc. Reports Operating Results (10-Q) Aug 10 2009 
CardioNet, Inc. Reports Second Quarter 2009 Financial Results Aug 05 2009 
CardioNet Inc. (BEAT) CFO Martin P Galvan buys 5,000 Shares May 18 2009 
CardioNet Inc. Reports Operating Results (10-Q) May 15 2009 
CardioNet Inc. (BEAT) CEO Randy H Thurman buys 5,555 Shares May 07 2009 
CardioNet Inc. (BEAT) CFO Martin P Galvan buys 1,000 Shares Mar 02 2009 

More From Other Websites
BioTelemetry, Inc. (NASDAQ: BEAT) to Ring The NASDAQ Stock Market Opening Bell Aug 13 2014
BIOTELEMETRY, INC. Financials Aug 08 2014
BIOTELEMETRY, INC. Files SEC form 10-Q, Quarterly Report Aug 01 2014
BioTelemetry Inc Earnings Call scheduled for 5:00 pm ET today Jul 31 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 31 2014
BioTelemetry, Inc. Reports Second Quarter 2014 Financial Results Jul 31 2014
Q2 2014 BioTelemetry Inc Earnings Release - 4:00 pm ET Jul 31 2014
BioTelemetry, Inc. to Release Second Quarter 2014 Earnings Results on July 31, 2014 Jul 22 2014
3 Stocks Under $10 Making Big Moves Jun 11 2014
BioTelemetry unit acquires assets of RadCore Lab Jun 05 2014
BioTelemetry Inc Stock Downgraded (BEAT) Jun 03 2014
Covance Posts In-line Q1 Earnings; Falls on Trimmed View May 08 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 07 2014
How BioTelemetry (BEAT) Stock Stands Out in a Strong Industry May 07 2014
BioTelemetry 's (BEAT) CEO Joseph Capper on Q1 2014 Results - Earnings Call Transcript May 06 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2014
Weakness Seen in The Spectranetics Corporation (SPNC) Estimates: Should You Stay Away? May 02 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Apr 04 2014
BioTelemetry, Inc. Announces the Acquisition of the Cardiac Patient Services Business of Biomedical... Mar 20 2014
BIOTELEMETRY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Mar 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK